An orally administered octapeptide studied as a 'tight-junction regulator' for reducing intestinal permeability, most notably in celiac-disease research.
Mechanism under study
Larazotide acts locally in the gut lumen as a zonulin antagonist, proposed to promote assembly of epithelial tight junctions and thereby reduce intestinal permeability ('leaky gut').
Research-reported dosing
Investigational (as larazotide acetate). Celiac-disease trials used 0.5 mg (500 mcg) orally before meals; a Phase 3 trial was halted for futility. Taken orally, not injected.
Administered orally in trials (as 0.5 mg capsules), not reconstituted for injection; as an illustration only, 5 mg of powder + 2 mL water = 2500 mcg/mL.
Open this mix in the calculator →Dosing figures describe how this compound appears in the research literature and research-community references. They are not a recommendation for human use.
Larazotide FAQ
What is Larazotide?
An orally administered octapeptide studied as a 'tight-junction regulator' for reducing intestinal permeability, most notably in celiac-disease research.
What is the half-life of Larazotide?
Minimal systemic exposure by design — it acts locally in the gut lumen and is poorly absorbed.
What is the research-reported dosing for Larazotide?
Investigational (as larazotide acetate). Celiac-disease trials used 0.5 mg (500 mcg) orally before meals; a Phase 3 trial was halted for futility. Taken orally, not injected.
How is Larazotide reconstituted?
Administered orally in trials (as 0.5 mg capsules), not reconstituted for injection; as an illustration only, 5 mg of powder + 2 mL water = 2500 mcg/mL.
Is Larazotide FDA-approved?
No — Larazotide is investigational and not FDA-approved. It is sold for laboratory research use only.
References
Related peptides
Thymosin Alpha-1
Immunomodulatory 28-amino-acid peptide
An immune-modulating 28-amino-acid peptide, marketed as Zadaxin in a number of countries. It is among the more clinically studied immune peptides, though it is not FDA-approved in the United States.
KPV
Alpha-MSH-derived tripeptide
A tripeptide fragment (Lys-Pro-Val) derived from the C-terminus of alpha-MSH, studied for anti-inflammatory effects, particularly in models of gut inflammation.
BPC-157
Synthetic pentadecapeptide
A stable synthetic peptide based on a partial sequence identified in gastric juice. It is one of the most-studied research peptides for connective-tissue and gut-lining repair in animal models.